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ABSTRACT: Both abnormalities in high energy phosphate metabolism and a
decreased oxidative enzyme capacity have been reported in skeletal muscle of stable
chronic obstructive pulmonary disease (COPD) patients. The first aim of this study
was to investigate whether these findings are present in anterior tibialis muscle and
whether or not they are associated. Abnormalities in mitochondrial structure and
function as well as signs of myopathy have been found during corticosteroid treat-
ment. The second aim of this study, therefore, was to investigate whether in COPD
patients prolonged use of low dose prednisolone has effects on muscle energy
metabolism and qualitative morphology.
In a cross-sectional study 15 COPD patients (forced expiratory volume in one
second (FEV1) 339 (meanSD) % predicted) who were steroid-naive (CORT-) were
compared with 10 healthy control subjects (HC) and with 14 COPD patients (FEV1
3011 % pred), who had been using oral prednisolone for at least 1 yr (CORT+).
It was found that adenosine triphosphate (ATP)/adenosine diphosphate was lower
in CORT- compared to HC (5.7 versus 6.2, p=0.03). Inosine monophosphate was de-
tected in 13 of 15 CORT- compared to 3 of 10 HC (p=0.004). However, although indi-
cations were found for an imbalance in production and utilization of ATP, comparing
CORT- and HC, no differences in oxidative (citrate synthase and 3-hydroxy-acyl-
coenzyme A dehydrogenase) and glycolytic (hexokinase, lactate dehydrogenase and
phosphofructokinase) enzyme capacities were found.
When, comparing steroid-treated and steroid-naive patient subgroups, no diffe-
rences in the above mentioned parameters of muscle energy metabolism and of muscle
qualitative morphology were found.
Eur Respir J 2000; 16: 247±252.
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Exercise intolerance and dyspnoea are the most frequen-
tly occurring complaints in patients with severe chronic
obstructive pulmonary disease (COPD). Weakness of both
skeletal and respiratory muscles contributes significantly to
these complaints [1]. Recently it has been shown that
muscle weakness in COPD patients can predominantly be
explained by muscle atrophy [2]. However, several stud-
ies suggested that exercise tolerance might also be impair-
ed by alterations in muscle energy metabolism [3±5].
Experimental evidence is accumulating that in COPD
patients muscle energy metabolism is already disturbed at
rest. JAKOBSSON et al. [6] found a decreased oxidative cap-
acity and an increased glycolytic capacity in quadriceps
femoris muscle. MALTAIS et al. [3] reported a decreased
oxidative capacity in quadriceps femoris muscle. In ano-
ther recent study [4], in tibialis anterior muscle, indica-
tions for an imbalance in adenosine triphosphate (ATP)
utilization and resynthesis were found, as suggested by
increased inosine monophosphate (IMP) levels, which
were negatively related with ATP/adenosine diphosphate
(ADP) ratios. However, in that study oxidative and gly-
colytic enzyme capacities were not investigated.
In view of the above mentioned findings in skeletal
muscle of COPD patients, it might be hypothesized that the
observed disturbances in high energy phosphate metabo-
lism in the tibialis anterior muscle are associated with dec-
reased oxidative enzyme capacities. Therefore, the first aim
of the current study was to investigate both high energy
phosphates and metabolic enzyme capacities in anterior
tibialis muscle comparing stable severe COPD patients
with healthy control subjects.
In experimental animal studies indications have been
found that glucocorticosteroids may affect muscle energy
metabolism. Several studies found alterations in muscular
mitochondrial structure, including enlargement [7], aggre-
gation and vacuolation [7, 8] of mitochondria. Further-
more, indications for impaired muscle glycogenolysis [9]
and increased glycogen synthesis [10, 11] have been pro-
vided. However, virtually no information is available
regarding muscle energy metabolism in humans using
long-term corticosteroid therapy.
In a recent human study histological abnormalities were
observed in biopsies of the quadriceps femoris muscle
of COPD patients with severe steroid-induced myopathy
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[12]. Alterations in qualitative morphology were found,
including increased variation of fibre diameters, increased
numbers of central nuclei and increased amounts of
connective tissue in between muscle fibres. In the above
mentioned study the doses of corticosteroids administered
were quite high. No studies are available investigating
muscle morphology in COPD patients using long-term
low dose corticosteroids. It might be hypothesized that
treatment with long-term low dose prednisolone leads to
altered muscle enzyme capacities, increased glycogen
levels and increased occurrence of myopathic features.
Therefore, the second aim of this study was to investigate
parameters of muscle energy metabolism and muscle
qualitative morphology comparing stable severe COPD
patients who never received maintenance treatment with
oral glucocorticosteroids with COPD patients using low
dose oral prednisolone for >1 yr.
Methods
Subjects
Fifteen COPD patients who never received maintenance
treatment with oral corticosteroids (CORT-) were compar-
ed with 10 healthy age-matched volunteers (HC). CORT-
patients were also compared with 14 COPD patients who
had been using oral prednisolone for at least 1 yr (CORT+).
None of the patients received steroid burst regimens within
3 months prior to the study. Part of the data was reported in
an earlier study [4], involving a larger patient group. All
patients had COPD [13] and had a forced expiratory
volume in one second (FEV1) expressed as a percentage
of predicted of <50%. Exclusion criteria were a history of
cardiac failure, distal arteriopathy, malignancy, endocrine,
hepatic or renal disease or use of anticoagulant drugs. All
patients were clinically stable at the time of the study.
Written informed consent was obtained and the study was
approved by the Medical Ethical Board of the University
Hospital Maastricht (the Netherlands).
Corticosteroid and concomitant treatment
Daily dose and duration of prednisolone treatment were
obtained using a standardized patient questionnaire. The
number of steroid burst regimens used in the year prior to
examination was noted. All data were checked in available
hospital files. COPD patients were treated with inhaled b2-
agonists (n=29), inhaled anticholinergics (n=24), inhaled
corticosteroids (n=25), and oral theophylline (n=22). None
of the patients were using >1,200 mg inhaled steroids per
day.
Collection and analysis of muscle biopsies
After an overnight fast, muscle biopsies were obtained
under resting conditions, while the subjects were breathing
room air. Under local anaesthesia, biopsies were taken from
anterior tibialis muscle, using a conchotome [14]. Samples
used for the determination of parameters of muscle ener-
gy metabolism were immediately frozen in liquid nitro-
gen and stored at -808C. The average weight of individual
muscle samples was (meanSD) 265 mg. After freeze-
drying adherent blood and connective tissue were remo-
ved. ATP, ADP, adenosine monophosphate (AMP) and
IMP were determined with a high performance liquid
chromatographic technique [15]. The detection level for
IMP was 0.06 mmol.kg-1 dry weight. Phosphocreatine
(PC) and creatine (C) were measured fluorometrically [16].
Glycogen was determined measuring its glucose residues
[16]. The values obtained were corrected for the amount
of free glucose present at the time of tissue sampling.
Oxidative enzymes were represented by citrate synthase
(CS), which is responsible for the entry of acetyl coen-
zyme A (CoA) into the citric acid cycle and 3-hydroxy-
acyl-CoA dehydrogenase (HAD) which regulates the
beta-oxidation of fatty acids. Glycolytic enzymes were
represented by hexokinase (HK), which is involved in glu-
cose phosphorylation, phosphofructokinase (PFK), which
is a rate limiting enzyme in glycolysis and lactate de-
hydrogenase (LDH), which is involved in lactate meta-
bolism. To determine maximal enzyme activities, the
frozen tissue sample was homogenized in a buffer, con-
taining (mmol.L-1): sucrose (25), ethylene diamine tetra-
acetic acid (2), tris-hydroxymethyl-amino methane (10,
pH 7.4). CS [17], HAD [18], HK [19], PFK [20] and
LDH [21] activities were assessed using a Cobas-BIO
autoanalyzer (Roche, Basle, Switzerland). Protein content
in the homogenates was measured with the microbicin-
choninic acid method of Pierce (Rockford, IL, USA) [22].
For histological examination each biopsy was oriented
longitudinally and was rapidly frozen in isopentane. Sam-
ples were stored at -808C. Cross sections were cut at 8 mm
by use of a cryostat kept at -208C. Sections were stained
with haematoxylin-eosin and were studied for myopathic
changes [23] by a blinded pathologist. The sections were
qualitatively scored for presence or absence of the follow-
ing morphological features: increased numbers of central
nuclei, increased variation of muscle fibre diameters, in-
creased numbers of split fibres, increased numbers of
vacuoles, increased numbers of abnormal mitochondria,
and increased amount of connective tissue.
Pulmonary function tests
FEV1 and the forced vital capacity were measured
(Masterlab; Jaeger, Wurzburg, Germany) until three repro-
ducible recordings were obtained. The highest values were
used for analysis. The diffusion capacity of the lung for
carbon monoxide (DL,CO) was measured by the single-
breath carbon monoxide method (Masterlab Transfer;
Jaeger). Total lung capacity and residual volume were
measured by body plethysmography (Masterlab Body;
Jaeger). Values were expressed as a percentage of reference
values [24]. Blood was drawn from the radial artery while
sub-jects were breathing room air. Blood gases were mea-
sured using a blood gas analyser (ABL 330; Radiometer,
Copenhagen, Denmark).
Anthropometric measures and maximal mouth pressu-
res
Body weight (BW) and height (Ht) were measured
standing barefoot. Body mass index (BMI) was calculated
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by dividing BW by Ht2. Fat-free mass (FFM) was de-
termined with a deuterium dilution method [25]. FFM
index (FFMI) was calculated by dividing FFM by Ht2. Fat
mass (FM) was calculated by subtracting FFM from BW.
FM was expressed as a percentage of BW. Respiratory
muscle strength was determined by maximal inspiratory
and expiratory mouth pressures (PI,max and PE,max, res-
pectively) [26].
Calculations and statistical analysis
Because protein content tended to be lower in CORT+
compared to CORT- patients and HC, muscle enzymatic
activity was related to protein content. The total adenine
nucleotides (TAN) was calculated by adding ATP, ADP
and AMP. Total muscle creatine was calculated by adding
PC and C. On analysis of qualitative morphology the pre-
sence of a morphological feature was scored 1 and absence
was scored 0. The total amount of morphological abnor-
malities was calculated by adding the scores of individual
morphological features. Comparisons between groups were
performed using the Mann Whitney U-test. Frequency data
were compared using the Chi-squared test. Linear regres-
sion analysis was used to study relationships between
parameters. Significance was determined at the 5% level.
Statistical analyses were performed using the SPSS for




Pulmonary function, anthropometric measurements and
maximal mouth pressures are listed in table 1. CORT- pa-
tients had severe airflow obstruction, marked air trapping,
moderate hyperinflation, reduced DL,CO and slightly re-
duced values of arterial oxygen with, on average, normo-
capnia. In the HC group, all lung function parameters
were in the normal range. Compared with the HC, in
CORT- patients the BMI was significantly lower because
of a significantly decreased FFMI, whereas the FM was
not different from that of the HC. Both PI,max and PE,max
were decreased in CORT- patients compared with HC. No
differences in lung function parameters, anthropometric
measures and maximal mouth pressures were found
between CORT- and CORT+ patients.
Medical treatment
CORT+ patients were using meanSD 7.44.8 mg, pred-
nisolone.day-1 (range: 5±17.5 mg) as maintenance treat-
ment. They were using this treatment for 4.85.7 yrs,
(range: 1±20 yrs). CORT+ and CORT- patients were
treated with 2.01.6 (range: 0±5) and 1.41.1 (range 0±3)
steroid burst regimens in the preceding year, respectively
(NS). The patient subgroups did not differ in concomitant
treatment.
High energy phosphates and related compounds
Values of muscle metabolites are summarized in table 2.
No significant differences were found between the CORT-
patient subgroup and the HC group in ATP, ADP, AMP, or
TAN. However, CORT-patients had significantly lower
ATP/ADP ratios compared to the HC group. IMP could be
detected in 13 of 15 CORT- patients compared with three of
10 HC (Chi-squared=8.4, p= 0.004). The mean IMP level
Table 1. ± Characteristics of chronic obstructive pulmo-
nary disease (COPD) patients and healthy controls
Controls CORT- CORT+
Subjects n 10 15 14
Age yrs 668 656 668
FEV1 % 1129 339* 3011
FVC % 1147 8618* 7920
DL,CO % 11522 5826* 5736
RV % 11314 20260* 20978
TLC % 1095 12521* 12920
Pa,O2 kPa 11.41.5 9.41.0* 9.11.0
Pa,CO2 kPa 4.60.5 5.20.6* 5.60.7
BMI kg.m-2 25.92.2 22.14.3* 23.33.0
FFMI kg.m-2 19.51.2 15.91.9* 16.21.8
FM % 245 279 307
PI,max cmH2O -10221 -7423* -6924
PE,max cmH2O 10119 8317* 8519
Data are presented as meanSD. CORT-: COPD patients not
using prednisolone; CORT+: COPD patients using predniso-
lone; FEV1: forced expiratory volume in one second; FVC:
forced vital capacity; DL,CO: diffusion capacity of the lung for
carbon monoxide; RV: residual volume; TLC: total lung ca-
pacity; Pa,O2: oxygen tension in arterial blood; Pa,CO2: carbon
dioxide tension in arterial blood; BMI: body mass index; FFMI:
fat-free mass index; FM: fat mass as a percentage of body
weight; PI,max: maximal inspiratory mouth pressure; PE,max:
maximal expiratory mouth pressure. FFMI and FM were
measured in eight controls, 10 CORT- and 10 CORT+ patients.
*: p<0.05 compared to controls.
Table 2. ± Muscle high energy phosphates and related
compounds
Controls CORT- CORT+
n 10 15 14
ATP 19.23.5 18.72.5 16.6 (3.5)
ADP 3.10.5 3.30.5 3.0 (0.6)
AMP 0.090.03 0.120.03 0.10 (0.03)
ATP/ADP 6.20.6 5.70.5* 5.6 (0.5)
TAN 22.43.9 22.23.0 19.7 (4.1)
PC 7210 8013 76 (19)
C 367 458* 42 (10)
PC/C 2.00.2 1.80.2 1.8 (0.4)
Ctot 10816 12520 118 (27)
IMP yes/no 3/7 13/2* 11/3
IMP 0.080.02 0.140.08* 0.160.13
Glycogen 28688 26864 24960
Values are presented as meanSD and are expressed as mmol.kg-1
dry weight. CORT-: chronic obstructive pulmonary disease
(COPD) patients not using prednisolone; CORT+: COPD pati-
ents using prednisolone; ATP: adenosine triphosphate; ADP:
adenosine diphosphate; AMP: adenosine monophosphate; TAN:
ATP+ADP+AMP; PC: phosphocreatine; C: creatine; Ctot: PC+
C; IMP: inosine monophosphate. Glycogen is expressed as
mmol glycosyl units.kg-1 dry weight. *: p<0.05 compared to
controls.
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in the 13 CORT- patients with detectable IMP was
0.140.08, ranging 0.06± 0.29 mmol.kg-1 dry weight. The
mean IMP level of the three HC with detectable IMP was
0.080.02, ranging 0.06±0.09 mmol.kg-1 dry weight. In
CORT- patients with detectable IMP a significant corre-
lation was found between IMP levels and the ATP/ADP
ratio (r=-0.72, p=0.006). C was significantly higher in
CORT- patients compared to HC. Comparing CORT- and
CORT+ patient subgroups, no significant differences were
found in muscle high energy phosphates or glycogen.
Muscle metabolic enzyme capacity
Muscle enzyme capacities are listed in table 3. No signi-
ficant differences in oxidative or glycolytic enzyme cap-
acities were found between the CORT- patient subgroup
and the HC group. In CORT- patients and HC a positive
correlation was found between CS and HAD enzyme cap-
acities (r=0.68, p=0.001). No significant relationships
were found between enzyme capacities and muscle high
energy phosphate contents. Comparing CORT- and
CORT+ patient subgroups no differences were found in
muscle enzyme capacities.
Qualitative morphology in muscle fibres
Qualitative morphological changes are listed in table 4.
In all of the subjects the sum of the morphological ab-
normalities varied between 0±3. No significant diffe-
rences in the occurrence of individual morphological
changes reflecting myopathic alterations, or in the sum of
all morphological changes, were found between the
CORT- patient subgroup and the HC group. Also com-
paring CORT- and CORT+ patient subgroups, no diffe-
rences in qualitative muscle morphology were found.
Discussion
In the present study, in anterior tibialis muscle, oxidative
and glycolytic enzyme capacities were not different in
CORT- patients and HC. These findings are in accordance
with GEA et al. [27], who did not find abnormalities in
enzyme capacities in deltoid muscle. However, in studies
examining quadriceps femoris muscle, a decreased oxida-
tive capacity as measured by CS [3, 6] and HAD [6] and
an increased glycolytic capacity as measured by PFK [6]
were found. With comparable patient characteristics,
other factors seem to be more important in causing the
discrepancies between the studies. In the above-men-
tioned studies, three different muscles were investigated,
which differ greatly in structure and function, tibialis
anterior muscle being primarily a postural muscle contai-
ning a high percentage of slow, type I muscle fibres
(70%), deltoid muscle having both tonic and phasic acti-
vity and containing 50±60% type I muscle fibres, and
quadriceps femoris muscle being primarily a locomotor
muscle containing only 40% type I muscle fibres [28].
In COPD patients both systemic factors such as hypoxia
and nutritional depletion and local factors, such as activity
level might influence muscle enzyme capacities. At present
it is unknown to what extent muscles of different fibre type
distribution and function are affected by the combination
of these factors. As for the latter factor, it is known that
complete immobilization causes a greater decrease in oxi-
dative capacity in predominantly type I muscles, compared
to predominantly type II muscles [29]. On the other hand it
is probable that the relative inactivity (but not complete
immobilization) that frequently occurs in severe COPD
patients affects a locomotor muscle to a greater extent
than a nonlocomotor muscle. This latter phenomenon
might explain the fact that decreased oxidative capacity
has been found in quadriceps femoris muscle, but not in
deltoid or tibialis anterior muscle of COPD patients.
In CORT- patients compared with the HC group eleva-
ted IMP levels and decreased ATP/ADP ratios were found
in resting anterior tibialis muscle. Furthermore, IMP levels
were inversely related with ATP/ADP ratios. These find-
ings have been reported earlier in a larger patient group [4].
Based on these findings, it was hypothesized that in COPD
patients, an imbalance in ATP utilization and resynthesis
already exists in resting anterior tibialis muscle. It is
noteworthy that signs of imbalance in ATP resynthesis
and utilization can be found, without accompanying
changes in the capacities of the most important oxidative
Table 3. ± Muscle enzyme capacities related to muscle
protein content
Controls CORT- CORT+
n 10 14 12
CS 5814 6916 7117
HAD 3812 4119 4017
HK 3.31.8 3.01.5 3.11.3
PFK 242114 27485 260161
LDH 465218 464173 413181
Protein 15130 14131 12835
Data are presented as meanSD in U.g protein-1. CORT-: chronic
obstructive pulmonary disease (COPD) patients not using pred-
nisolone; CORT+: COPD patients using prednisolone; CS:
citrate synthase; HAD: 3-hydroxyacyl-coenzyme A dehydro-
genase; HK: hexokinase; PFK: phosphofructokinase; LDH: lac-
tate dehydrogenase. Protein is expressed as mg.g-1 wet weight.
Table 4. ± Abnormalities in qualitative muscle morpho-
logy
Controls CORT- CORT+




Increased variation in muscle
fibre diameters
30 27 9
Increased numbers of split
fibres
10 7 9
Increased numbers of vacuoles 10 0 0
Increased numbers of abnormal
mitochondria
0 0 0
Increased amount of connective
tissue
0 0 0
Sum of all myopathic features
0 30 57 55
1 30 29 27
2 40 7 18
3 0 7 0
Data are presented as percentages. CORT-: chronic obstructive
pulmonary disease (COPD) patients not using prednisolone;
CORT+: COPD patients using prednisolone.
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and glycolytic enzymes. This suggests that other factors
play a role in the observed disturbances in muscle high
energy phosphate metabolism.
The effect of low dose maintenance treatment with oral
prednisolone on parameters of muscle energy metabolism
was evaluated comparing CORT- and CORT+ patient sub-
groups. No differences in muscle high energy phosphate
levels were found. Based on electron microscopic studies
reporting structural changes in mitochondria, it was hypo-
thesized that oxidative metabolism might be impaired
during use of corticosteroids. However, in the present
study no differences in oxidative and glycolytic enzyme
capacities were found between patient subgroups. In ac-
cordance with these findings, in rat muscle, no alterations
of CS and PFK capacity were found during prolonged use
of prednisolone [30]. In contrast to the current findings, in
patients with rheumatoid arthritis using long-term pred-
nisolone (7.5±10 mg), decreased CS and HAD capacities
were found in quadriceps femoris muscle [31]. However,
in the quoted latter study only 37.5% type I fibres were
found. Because it is unlikely that this decrease was solely
caused by the use of corticosteroids, this finding suggests
that other factors, such as inactivity might have contri-
buted.
In most experimental studies evaluating corticosteroid
induced changes in muscle metabolism, elevated muscle
glycogen levels were found [9, 10, 30]. This finding has
been confirmed in a human study by FERNANDEZ-SOLA et
al. [11], examining quadriceps femoris muscle of patients
with bronchial asthma on chronic treatment with predni-
solone (mean daily dose 17.3 mg). Therefore, it is notable
that in the present study, no differences in muscle gly-
cogen levels were found comparing CORT- and CORT+
patients.
Discrepancies between the above mentioned studies
and the current study might have been caused by the fact
that in the former studies higher dosages of corticosteroids
were used. Furthermore, in experimental studies steroid-
induced changes were found to be more extensive in type
II compared to type I muscle. Therefore, the effect of
corticosteroids on anterior tibialis muscle might be less
than expected in muscles containing more type II fibres.
In agreement with FERNANDEZ-SOLA et al. [11], but in
contrast to DECRAMER et al. [12], no differences in para-
meters of qualitative muscle morphology were found be-
tween CORT- and CORT+ patients in the present study.
Although comparable qualitative morphological features
were assessed, the current study cannot readily be com-
pared with the latter study, in which a higher dose of
corticosteroids was used (14.2 mg methylprednisolone)
and a predominantly type II muscle was analysed. Fur-
thermore, the subgroup of patients in the study by DE-
CRAMER et al. [12] that showed myopathic morphological
features in the muscle biopsy, suffered from severe ske-
letal and respiratory muscle weakness. Unfortunately, in
the present study, skeletal muscle function was not
assessed. However, mouth pressures were not different
between the patient subgroups.
In the present study, some morphological abnormalities
were also found in HC. Because an increased number of
central nuclei can also be found near a myotendinous
junction [23], it could be speculated that this phenomenon
be partly explained by the location of the sample site.
However, because care was taken to obtain biopsies from
the belly of the muscle and because no associated in-
creased amount of fibre splitting was present, this ex-
planation seems improbable.
In conclusion, in tibialis anterior muscle of stable
chronic obstructive pulmonary disease patients, no altera-
tions in oxidative and glycolytic enzyme capacities were
found, despite the fact that indications were found for an
imbalance between the utilization and resynthesis of mus-
cle adenosine triphosphate. Furthermore, a comparison be-
tween chronic obstructive pulmonary disease patients who
never used maintenance treatment with glucocorticoster-
oids, and chronic obstructive pulmonary disease patients
using maintenance treatment with low dose prednisolone
showed no effect of this treatment on parameters of muscle
energy metabolism and on qualitative muscle morphology.
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